LFMDP — LifeMD, Inc.

LifeMD, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $50.2 million, exceeding guidance of $48 million to $49 million, but flat compared to $50.9 million in Q1 2025.
• Active Subscribers: Over 365,000, with a net addition of 42,000 in Q1, the largest quarterly increase in company history.
• Gross Margin: Expanded by approximately 420 basis points to 88%, attributed to lower shipping and fulfillment costs.
• Net Loss: $9.6 million, or $0.20 per diluted share, compared to a loss of $2.4 million, or $0.06 per diluted share, in the prior year.
• Adjusted EBITDA: Loss of approximately $4.5 million, in line with guidance, compared to a positive adjusted EBITDA of $3.7 million in the prior year.
• Cash Position: $34.5 million in cash, no debt, and a $30 million undrawn revolving credit facility.

2. Strategic Updates and Business Highlights

• Growth in Weight Management: Significant growth with a 120% sequential increase in sign-ups. The company is positioned to benefit from the expanding GLP-1 therapy market.
• Women’s Health Program: Subscriber count grew over 7x from Q4, with strong retention rates above 80%. Plans to introduce new compounded pharmacy products focused on hormone and bone health.
• RexMD and Men’s Health: Approximately 215,000 active patients, with growth in various categories, particularly sleep.
• AI Integration: Ongoing deployment of AI to enhance operational efficiency and patient care.
• Pharmacy and Insurance Expansion: The pharmacy is processing about 20,000 prescriptions per month, with plans to expand offerings and insurance coverage, targeting 230 million covered lives by month-end.

3. Forward Guidance and Outlook

• Full-Year 2026 Guidance: Revenue expected between $220 million and $230 million, with adjusted EBITDA of $12 million to $17 million. Anticipation of returning to adjusted EBITDA profitability in the second half of the year.
• Q2 Revenue Guidance: Projected between $47 million and $50 million, with adjusted EBITDA ranging from negative $2 million to positive $1 million.
• Long-Term Growth: Expected annualized run-rate revenue exceeding $250 million and adjusted EBITDA exceeding $25 million by year-end.

4. Bad News, Challenges, or Points of Concern

• Year-over-Year Revenue Decline: Revenue was flat compared to the prior year, primarily due to a shift from compounded GLP-1s to branded drugs, impacting unit economics.
• Increased Marketing Expenses: Selling and marketing expenses rose 34% year-over-year, which pressured EBITDA in Q1.
• Competitive Pressures: The uptake of new oral therapies is slower than expected, and the company faces challenges in transitioning patients from compounded to branded medications.

5. Notable Q&A Insights

• Partnerships with Novo and Lilly: Management expressed optimism about evolving relationships with these pharmaceutical companies, focusing on compliant strategies to enhance patient access to therapies.
• Insurance Programs: Significant improvements in retention rates and customer acquisition costs for insurance-supported patients, with a noted 10% improvement in retention.
• Market Dynamics: The company is adapting to changes in the market, including a shift towards self-pay programs, which are performing better than anticipated.
• Future Initiatives: Plans to expand pharmacy offerings and improve operational efficiencies are expected to drive revenue and EBITDA growth in the latter half of the year.

Overall, LifeMD, Inc. reported a strong start to 2026 with significant subscriber growth and strategic advancements, despite facing challenges related to revenue dynamics and increased marketing costs. The company remains optimistic about its future growth prospects, particularly in the weight management and women’s health sectors.